Scienture (NASDAQ:SCNX – Get Free Report) and Inotiv (NASDAQ:NOTV – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and target prices for Scienture and Inotiv, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scienture | 1 | 0 | 0 | 0 | 1.00 |
| Inotiv | 1 | 0 | 1 | 0 | 2.00 |
Inotiv has a consensus price target of $5.00, suggesting a potential upside of 275.94%. Given Inotiv’s stronger consensus rating and higher possible upside, analysts plainly believe Inotiv is more favorable than Scienture.
Volatility & Risk
Institutional and Insider Ownership
5.7% of Scienture shares are owned by institutional investors. Comparatively, 18.2% of Inotiv shares are owned by institutional investors. 49.7% of Scienture shares are owned by insiders. Comparatively, 7.8% of Inotiv shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Scienture and Inotiv’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scienture | -10,364.22% | -24.47% | -19.30% |
| Inotiv | -15.63% | -15.74% | -3.28% |
Earnings and Valuation
This table compares Scienture and Inotiv”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scienture | $128,202.00 | 127.91 | $9.07 million | ($2.71) | -0.29 |
| Inotiv | $505.30 million | 0.09 | -$108.44 million | ($2.70) | -0.49 |
Scienture has higher earnings, but lower revenue than Inotiv. Inotiv is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Summary
Inotiv beats Scienture on 10 of the 14 factors compared between the two stocks.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
About Inotiv
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
